Summary
Introduction
Familial aggregation is a well-recognized epidemiological feature of multiple sclerosis and there is now substantial evidence from twin studies (Bobowick et al., 1978; Williams et al., 1980; Ebers et al., 1986; Kinnunen et al., 1987; Mumford et al., 1994) , candidate gene population association (Jersild et al, 1972) and linkage studies (Ebers et al, 1982; Kellar-Wood et al, 1995; Wood et al, 1995a, b) that this reflects the contribution of genetic factors to disease aetiology. With increased interest in the genetic basis for susceptibility in multiple sclerosis has come a demand both from patients and physicians for a clear statement on recurrence risks for different categories of relatives; this information allows affected individuals and their families to be counselled and permits computations of the epidemiological resources required for definitive genetic linkage studies. Contemporary information on familial disease within the United Kingdom is limited, and recurrence risks generated from cohorts which are not population based are inappropriate for general application. In addition, estimated risks may not be stable over time as a result of migration patterns and their consequential effects on the genetic profile within a population.
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The most accurate way of establishing recurrence risks in a disease such as multiple sclerosis which has a variable age of onset, where familial recurrence rates do not fit any clearly understood model of inherited disease, and for which there is no specific diagnostic test, is to follow all relatives of each proband prospectively. However, as an alternative, proportions of affected relatives can be established in crosssectional studies from which lifetime risks are calculated taking into account the known age-of-onset distribution of the disease.
Methods
The East Anglian register of multiple sclerosis was established in 1990 initially reporting epidemiological data on the south and east of the county of Cambridgeshire. It has subsequently been expanded and was last updated in 1993. Epidemiological data, as well as details of case ascertainment and study methodology, have previously been described (Mumford etal, 1992; Robertson etal, 1995a) . Pedigrees were routinely obtained on prevalent patients with definite and probable multiple sclerosis (Poser et al., 1983) , as well as suspected disease (those thought to have demyelinating disease but without radiological or neurophysiological evidence for a lesion at more than one site). One affected individual (the proband) from each family was asked to provide year of birth, present age or age-at-death, and disease status on each relative in a series of pre-designated categories; inclusion in the statistical analysis was allowed only if all of this information was known. All pedigrees were obtained after personal contact with the index patient and those individuals who were unable to provide complete pedigree information on initial consultation were issued with a standardized questionnaire. Only full biological relatives were considered, so that three affected half siblings identified in this study were not included. In addition, cases of familial disease were routinely reported to a central register by all practising clinicians, as a means of ensuring full ascertainment of familial disease in the population. During the 4-year period of the study, a substantial number of new diagnoses were made in the relatives of probands initially considered to have sporadic disease. Where an additional family history of multiple sclerosis was reported, the affected relative was clinically assessed by a member of the neurological department and the results of paraclinical investigations reviewed in order to assign the appropriate diagnostic category. If the relative was geographically distant or deceased, arrangements were made for review of clinical notes or death certificates. Relatives without confirmatory documentary evidence of disease were only included in the affected category if the historical evidence provided by other family members was typical of multiple sclerosis. Affected relatives were defined as those with definite, probable or suspected disease; care was taken to ensure that families were represented by a single proband and these were assigned in order of ascertainment from successive prevalence data.
Statistical methods Recurrence risks
A number of methods have previously been used to report recurrence rates in relatives. The prevalence of affected living relatives may be calculated; alternatively, crude unadjusted recurrence risks can be calculated for each category of relative taking into account both living and deceased individuals. Both methods are likely to underestimate the lifetime risk for developing the disease since simple prevalence data fail to take into account the fact that certain relatives may not have achieved the age of maximum risk. Lifetime recurrence risks for each relative class can be estimated by dividing the number of affected relatives by the adjusted number of such relatives at risk. This takes account of the ages, (a), to which relatives are observed. If F(a) is the cumulative age-at-onset distribution of multiple sclerosis, then any relative observed to a contributes (a) to the denominator for the recurrence risk. We estimated the cumulative age-at-onset distribution from the clinical records of 1226 patients assessed in Cambridge; age-at-onset distribution varied from 0.0 at age 7 years to 1.0 at age 63 years, the oldest age at which the first symptoms of multiple sclerosis have manifested in the Cambridgeshire population. This model requires that the pattern of familial recurrence is predictive of recurrence for the future, and that the age-of-onset of relatives will be the same as that of probands. In order that risk may be more accurately assigned to individuals within each clinical setting, a simple age adjustment that may be applied to individual cases is provided.
Results
Attempts were made to contact all 890 patients (female:male ratio 2.4) who were prevalent on July 1, 1993 and listed on the Cambridgeshire Multiple Sclerosis Register. Pedigrees were obtained for 679 (76.3%) patients of whom five had a relative who was also registered and hence these families were dually ascertained; duplicate index cases were all relatives of female probands-a father, two brothers, one sister and a maternal uncle. The pedigrees of 674 unrelated index cases (204 males and 470 females; female:male ratio 2.3) were therefore included for statistical analysis. Complete information, including date of birth and present age or age at death, was available for 11 391 relatives (male probands, n = 2948; female, n = 8443). The mean size of the pedigrees was 17 (males n = 16, females n = 18; range 0-79). One hundred and fifty-nine probands (23.8%) initially reported the possibility of 193 affected family members. Evidence from further investigation rejected the diagnosis in 65 relatives, usually because of insufficient supporting evidence or occasionally because an alternative diagnosis was confirmed. We therefore identified 128 additional first-, second-or thirddegree affected relatives, of which five out of 128 (3.9%) had suspected disease, based on direct observations, or a history typical of multiple sclerosis obtained from relatives. Crude, unadjusted, age-adjusted and age-specific recurrence risks are presented for all probands (Table 1 ) and outlined in more detail for female and male probands (Tables 2 and 3 , respectively); all are presented with 95% confidence intervals.
Combining pedigree analysis for both male and female probands eliminates unexpected results such as the high rate for daughters of male probands (Table 1 ). The highest ageadjusted recurrence risk was for sisters, followed by brothers, and a comparable rate was observed both for parents and offspring (2.05% and 1.83%, respectively). For female probands (Table 2) the parental age-adjusted risk was similar for both mothers and fathers at 1.80% and 1.85% (combined 1.82%), respectively. The highest risk was for female siblings (5.13%); despite age adjustment, the risk in offspring did not rise above 0.81% and was lower than the parental risk. No affected nephews, but six affected nieces, were identified, resulting in a combined adjusted risk of 1.33% for nieces/ nephews. Equivalent rates after age adjustment were also observed for aunts/uncles and first cousins (0.84% and 0.95%, respectively). Parental rates were slightly higher in male probands (Table 3) at 3.17%, but lower for sisters (2.54%) and brothers (3.63%) than for female probands. The highest risk was for daughters of male probands where three out of 143, on whom complete information was available, were affected and all had clinically definite disease. Clearly the risk that a clinically normal individual relative will be subsequently affected diminishes with age and, therefore, age-specific recurrence risks for unaffected relatives were also derived ( Table 4) .
The reduction in risk changes from 2.77% [relative risk (RR) 9.2] in first-degree relatives to 1.02% (RR = 3.4) and 0.88% (RR = 2.9) in second-and third-degree relatives, compared with a background adjusted lifetime risk of 0.30% (RR= 1.0; males 0.13%, females 0.66%; Table 5 and Fig. 1 ). No significant difference was observed between risks for maternal (1.05%) and paternal (1.15%) relatives (Table 5 ). The reduction in risk with genetic distance from the proband was less systematic than expected in female probands, with first-degree relatives having an age-adjusted risk of 2.64% but with only minimal difference between second-and third-degree relatives (0.94% and 0.95%, respectively). The risk in male probands for first-, secondand third-degree relatives reduced from 3.09% to 1.27% and 0.65%, compared with a background adjusted risk in the Cambridgeshire population of 0.13%. Roberts (1991) identified one out of 214 first-degree, two out of 578 second-degree and two out of 499 thirddegree affected relatives of probands resident on the Orkney Islands. More recently, Sharpe and colleagues (1995) reported a familial incidence rate of 5% for first-degree relatives of affected patients on the Channel Islands, and Swingler (1989) identified 43 out of 301 patients in south east Wales who reported another affected member. It can be seen from the manner in which these data are presented that direct comparisons with our recurrence risks are not appropriate but one pattern that does emerge is the rise of familial recurrence rate with time from 5.7% (McAlpine et al., 1955) in 1946 to 19% in this study from Cambridgeshire. It seems unlikely that our knowledge of relatives is better now than in the closer knit and more stable communities of the earlier part of this century, so this difference is likely to be the result of improved ascertainment and establishing the diagnosis in milder cases; a change in genetic susceptibility to multiple sclerosis with time seems less likely.
Comparison of recurrence rates for multiple sclerosis estimated outside the United Kingdom reveals substantial differences between geographically and ethnically distinct populations that cannot be explained by study methodology alone and may well represent differences in the genetic contribution to disease aetiology within different populations. Sadovnick et al. (1988) reported a familial incidence of 21.9% in first-second-and third-degree relatives for a clinic based population in Vancouver; in London, Ontario only 12.9% of patients in a similar clinic had an affected relative (Ebers, 1983) and the incidence in a 1979 epidemiological study in Iceland was 14.9% (Gudmundsson, 1971 ). For contemporary cross-sectional epidemiological studies in Northern Europe, a figure of ~15% seems agreed, although small studies of genetically stable populations whose genealogical associations have been extensively investigated report figures as high as 29% (Wikstrom et al, 1994) and even 66% (Binzer et al., 1994) . The specific reasons for local differences in recurrence risks are not clear but Davenport (1922) , using data from the United States Armed Forces, suggested that the distribution of multiple sclerosis within the United States matched the geographical pattern of immigration from Scandinavia indicating that recurrence risks may also be related to ethnicity. Racial differences in susceptibility have long been recognized and there are several striking reports of low prevalence in genetically isolated populations within recognized areas of high frequency (Hoestler, 1974) . The low disease frequency in populations not dominated by northern European genetic stock may also be mirrored by decreased familial incidence (Yu et al., 1989) . Conversely, a number of studies have concentrated on the increased incidence of the disease amongst populations migrating from low to high prevalence areas (Elian and Dean, 1987; Kahana et al., 1994) which may result from a change in environmental factors, although it is difficult to control precisely for the effect of genetic admixture.
Here we report the results of the first United Kingdom study in which recurrence rates were examined within a sufficiently large population to provide figures for counselling individual patients. We have derived age-specific rates which can be applied to individuals younger than the usual age of presentation of multiple sclerosis. Relative risks can be calculated for all categories of relatives including monozygotic twins, using figures from the recent United Kingdom survey of multiple sclerosis in twins , although this was not strictly population based. Despite access to a large number of probands, the small numerators in each category result in wide confidence intervals. Another potentially confounding factor is preferential recall of affected relatives; although unlikely to alter figures relating to nuclear family members, this may have the effect of artificially inflating rates for more distant family members in whom the denominator is relatively small. One example of this is the apparant excess of maternal compared with paternal cousins, which is accounted for in part by better knowledge of the maternal than paternal line amongst probands (mothers 92.7%, fathers 90.8%), a factor which we found less problematic than others (Sadovnick et al., 1988) . Perhaps mothers are better witnesses of family pedigrees.
We collected pedigrees from >75% of all probands in a prevalent population and are confident that the sample is representative of the population as a whole. Our declared interest in familial disease relating to a United Kingdom wide genetic linkage study may have resulted in high ascertainment of recurrence risks, but our results are consistent with other family studies which used similar methods. Sadovnick et al. (1988) studied 815 consecutive patients attending the multiple sclerosis clinic in Vancouver, and Koch-Henrikson (1989) performed a similar but smaller pedigree analysis from cross-sectional data confining the analysis to siblings.
The analysis of familial recurrence in multiple sclerosis depends on accurate assignment of disease status. We relied heavily on the recall of probands and their knowledge of disease status in relatives; ours is therefore a study of phenotype rather than the disease process. However, we did include relatives with suspected disease. In practice this has little effect on recurrence risk but (in our view) is biologically more accurate, since longitudinal data within our cohort suggest that individuals with this classification of disease progress to definite or probable disease at a rate of 7% per year. Radiological lesions compatible with multiple sclerosis are seen in clinically unaffected monozygotic and dizygotic twins and in siblings within multiplex families (Tienari et al., 1992) . The relevance of this finding is not yet clear but these lesions may represent sub-clinical disease which will become clinically apparent with time; clearly it is not possible to scan unaffected relatives in a large population based cohort. Recurrence rates can only be applied generally to the population under study if it is considered that the disease is aetiologically homogeneous. Clinical and radiological differences between primary progressive and relapsing-remitting disease (Thompson etal., 1991) , geographical differences in phenotype (Shibasaki et al., 1981) , and reports of the association of a multiple sclerosis-like illness with certain pathogenic Lebers mitochondrial mutations all hint at the possibility of disease heterogeneity. Extended studies of concordant sibling pairs also indicate that the risk to relatives may not be spread evenly amongst families and high risk pedigrees exist that may have different clusters of susceptibility genes. (Doolittle et al, 1990) Recurrence risk data from population based series can be used to estimate the number of genes which confer susceptibility and their most likely mode of inheritance, and to establish the resources required to provide definitive information on the genetic contribution to disease aetiology. (Sadovnick, 1994; Robertson et al, \995b) The lifetime recurrence risks for a cross-sectional sample of the United Kingdom and Cambridgeshire population range from 0.3% in the general population to 31% in monozygotic twins (RR = 103.2). The increased risk observed for second-and third-degree relatives supports the interpretation that genetic factors influence recurrence, since individuals outside the nuclear family are less likely to have shared the same environmental exposure. Increase in relative risk with genetic proximity to the proband provides the basis for application of recognized models of inheritance to observed patterns of recurrence. Results of family studies performed so far have been able effectively to exclude all but a polygenic mode of inheritance, and autosomal dominant or recessive single locus with low penetrance; but most evidence now suggests that disease susceptibility is controlled by several genes.
Working with a large population-based sample of wellvalidated and unrelated patients with multiple sclerosis, we have produced an age-adjusted table of recurrence risks for defined categories of relatives which can reliably be used for counselling in a clinical setting.
